Read more
Whether to promote platelet recovery or to ameliorate the complications of cancer and the side effects of chemotherapy, hematopoietic growth factors (HGFs) now account for more than $5 billion per year of the US health care budget. In Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Therapeutics, leading oncologists, hematologists, and nephrologists comprehensively review the role of HGFs in clinical practice, explain the molecular basis of their effects, and consider potential future developments. The authors focus on the use of HGFs in oncology, describing their cutting-edge application to patients with lung cancer, Hodgkin's and non-Hodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, AIDS-related malignancies, myelodysplastic syndromes, and aplastic anemias. Among the HGFs described are granulocyte colony-stimulating factor, erythropoietc factors, thrombopoietic factors, and stem-cell factor and its receptor, c-kit. To complete their survey, the contributors also consider the safety and economic implications of HGFs and the future potential for HGF antagonists in oncology.
Comprehensive and up-to-date, Hematopoietic Growth Factors in Oncology: Basic Science and Clinical Practice offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombocytopenia in patients with malignant and nonmalignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit.
List of contents
I. Basic Research.- 1 Introduction to Hematopoietic Growth Factors: A General Overview.- 2 Animal Models of Hematopoietic Growth Factor Perturbations in Physiology and Pathology.- 3 The Jak/Stat Pathway of Cytokine Signaling.- 4 Small-Molecule and Peptide Agonists: A Literature Review.- II. Hematopoietic Growth Factors.- 5 Granulocyte Colony-Stimulating Factor.- 6 Erythropoietic Factors: Clinical Pharmacology and Pharmacokinetics.- 7 Thrombopoietin Factors.- 8 Stem Cell Factor and Its Receptor, c-Kit.- 9 Hematopoietic Growth Factors: Preclinical Studies of Myeloid and Immune Reconstitution.- III. Use of Hematopoietic Growth Factors in Oncology.- 10 Commentary on the ASCO and ESMO Evidence-Based Clinical Practice Guidelines for the Use of Hematopoietic Colony-Stimulating Factors.- 11 Neutropenia and the Problem of Fever and Infection in Patients With Cancer.- 12 Thrombocytopenia and Platelet Transfusions in Patients With Cancer.- 13 Hematopoietic Growth Factors in Lung Cancer.- 14 Role of Hematopoietic Growth Factors As Adjuncts to the Treatment of Hodgkin's and Non-Hodgkin's Lymphomas.- 15 Use of Granulocyte Growth Factors in Breast Cancer.- 16 Role of Cytokines in the Management of Chronic Lymphocytic Leukemia.- 17 Hematopoietic Growth Factor Therapy for Myelodysplastic Syndromes and Aplastic Anemia.- 18 Use of Hematopoietic Growth Factors in AIDS-Related Malignancies.- IV. Safety and Economic Implications.- 19 The Safety of Hematopoietic Growth Factors.- 20 Long-Term Safety of Filgrastim in Chronic Neutropenias.- 21 Economics of Hematopoietic Growth Factors.- V. Future Directions.- 22 Potential for Hematopoietic Growth Factor Antagonists in Oncology.- Acronyms and Selected Abbreviations.
Summary
Reviews the role of HGFs in clinical practice, explains the molecular basis of their effects, and considers potential developments. This book focuses on the use of HGFs in oncology, describing their application to patients with lung cancer, Hodgkin's and nonhodgkin's lymphoma, breast cancer, chronic lymphocytic leukemia, and more.
Additional text
"Comprehensive and up-to-date...offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombotopenia in patients wit malignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit." - Tumori
Report
"Comprehensive and up-to-date...offers an integrated survey of the role of HGFs in treating and preventing anemia, neutropenia, and thrombotopenia in patients wit malignant diseases, along with fresh insights into drug development and how basic discoveries in this area can be optimally translated into clinical benefit." - Tumori
